Результаты поиска

A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Neutropenic Enterocolitis as a Complication of Autologous Stem Cell Transplant in Patients With Multiple Myeloma: A Case Series.

Neutropenic enterocolitis (NE) is a rare but severe complication occurring in neutropenic patients undergoing intensive chemotherapy. Mortality is high, so early diagnosis is required to start urgent medical or surgical treatment. Data analysis of the development of NE after hematopoietic stem cell transplantation remains scarce. The aim of this case series is to discuss five out of 100 patients receiving autologous stem cell transplants (ASCTs) for multiple myeloma complicated with NE between 2016 and 2020 in the hematology department of the Cheikh Khalifa International University Hospital, C

Совпадение в полном тексте источника
… Management must be multidisciplinary associating hematologists, oncologists, gastroenterologists, radiologists, and biologists. Early diagnosis and treatment in the cases highlighted in our report allowed a good evolution without complications. …

A registry study of relapsed or refractory multiple myeloma pre-exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38-targeted monoclonal antibody therapy in England.

Some patients with multiple myeloma are receiving treatment in clinical practice in England after prior exposure to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. We investigated the characteristics of these patients, their outcomes, and the salvage therapies they received using the national cancer registry for England and linked healthcare data. After a median follow-up time of 6.4 months from T 0, median overall survival and time to next treatment were 8.2 and 5.3 months, respectively. This real-world data provide useful clinical insight into a littl

Негативные события, связанные с лечением, заменяют собой реакцию на блокаду контрольно-пропускных пунктов.

ОКРУЖАЮЩАЯ СРЕДА: Иммунная блокада контрольно-пропускных пунктов (МКБ) дает надежду многим пациентам, страдающим раком на поздней стадии, однако ее показатель реагирования остается неясным. Мы разработали гипотезу о том, что связанные с лечением неблагоприятные явления (TRAE) могут предсказать объективную долю ответов (ORR) на ICB. Мы рассчитали операционную против любого класса. 3 в адрес 5 (В тыс.G3-5) ТРАЭ различных типов рака путем проведения мета-анализа с использованием линейной регрессии. Результаты: Мы определили 113 приемлемые исследования, включая 25 - виды негативов, обработанных с

Establishing Hematopoietic Stem Cell Transplant Unit in Resource Limited Setting: A Critical Analysis of Indian Council of Medical Research 2017 Guidelines.

The scope and application of hematopoietic stem cell transplantation are increasing. With advancement in science and close cooperation of health centers, HSCT units are coming up in new developing and underdeveloped countries. India hosts many HSCT units and often provides financially viable option for HSCT to foreign patients as well. Recently Indian Council of Medical Research (ICMR) issued a guideline about HSCT unit in India. This review article discusses establishment of new HSCT unit in resource limited setting. Subsequent implication of ICMR guideline has been done.

Expedited drug review process: Fast, but flawed.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

The Impact of Iron on Cancer-Related Immune Functions in Oncology: Molecular Mechanisms and Clinical Evidence.

Iron metabolism plays a dual role in cancer, serving as an essential nutrient for cellular functions and a potential catalyst for tumor growth and immune evasion. Here, we cover the complex interplay between iron levels within the serum or in the microenvironment and cancer therapy, focusing on how iron deficiency and overload can impact immune function, tumor progression, and treatment efficacy. On the one hand, we highlight iron deficiency as a factor of primary immune responses and its adverse effects on anti-cancer immunotherapy efficacy. On the other hand, we also stress the impact of iro

Совпадение в полном тексте источника
… By integrating iron management into cancer therapy protocols, oncologists can optimize treatment efficacy and improve outcomes for cancer patients. … Impact of Iron-Deficiency Management on Quality of Life in Patients with Cancer: A Prospective Cohort Study (CAMARA Study) Oncologist. 2022;27:328–333. doi: 10.1093/oncolo/oyac005. 15. Knight K., Wade S., Balducci L. …

Utilization and quality of palliative care in patients with hematological and solid cancers: a population-based study.

BackgroundPalliative care (PC) contributes to improved end-of-life care for patients with hematologic malignancies (HM) and solid tumors (ST) by addressing physical and psychological symptoms and spiritual needs. Research on PC in HM vs. ST patients is fragmented and suggests less use.MethodsWe analyzed claims data of all deceased members of a large German health insurance provider for the year before death. First, we analyzed the frequency and the beginning of different types of PC and compared patients with HM vs. ST. Second, we analyzed the adjusted impact of PC use on several end-of-life q

Совпадение в полном тексте источника
… Hematologic oncologists recognize the value of hospice care for HM patients, but the dependency on blood transfusions affects the decision to refer to hospice care and the timing of that referral, as revealed in a survey by Odejide et al. (Odejide et al. 2017 ). … Oncologist 26(1):77–83. 10.1002/onco.13515 32915490 10.1002/ONCO.13515 PMC7794182 Moreno-Alonso D Porta-Sales J Monforte-Royo C Trelis-Navarro J Sureda-Balarí A Fernández De Sevilla-Ribosa A Palliative care in patients with haematological neoplasms: an integrative systematic review Palliat Med 2018 …

The needs of cancer patients during the COVID-19 pandemic-psychosocial, ethical and spiritual aspects-systematic review.

The COVID-19 pandemic resulted in unprecedented changes in the functioning of the health care system, which were connected with the occurrence of new challenges for both the health care system's employees and for the patients. The purpose of the present article is to analyze the needs of persons with oncological diseases. Taking into account the multiple aspects of the term health, psychological, social, and existential needs of the patients were analyzed. This article is directed mainly at persons who remain in a direct therapeutic relation with a patient. It is to facilitate recognizing the

Challenges and Advances in Managing Thrombocytopenic Cancer Patients.

Cancer patients have varying incidence, depth and duration of thrombocytopenia. The mainstay of managing severe chemotherapy-induced thrombocytopenia (CIT) in cancer is the use of platelet transfusions. While prophylactic platelet transfusions reduce the bleeding rate, multiple unmet needs remain, such as high residual rates of bleeding, and anticancer treatment dose reductions/delays. Accordingly, the following promising results in other settings, antifibrinolytic drugs have been evaluated for prevention and treatment of bleeding in patients with hematological malignancies and solid tumors. I

Deciding to Enrol in a Cancer Trial: A Systematic Review of Qualitative Studies.

BackgroundClinical trials are essential for the advancement of cancer treatments; however, participation by patients is suboptimal. Currently, there is a lack of synthesized qualitative review evidence on the patient experience of trial entry from which to further develop decision support. The aim of this review is to synthesise literature reporting experiences of participants when deciding to enrol in a cancer clinical trial in order to inform practice.MethodsA systematic review and meta-synthesis of qualitative studies were conducted to describe the experiences of adult cancer patients who d

Совпадение в полном тексте источника
… . | Focus Groups | Thematic Analysis | 26 participants (20 patients; 6 medical oncologists) | Lung, Breast & Prostate Cancer | Patients assessed the risks alongside the benefits of the clinical trial. Trust in doctor’s recommendation and severity of patients disease influenced decision making. … Sanders. (2000) 44 | UK | To investigate patients treatment decision-making process. | Observations; In-depth Interviews | Thematic Analysis | Observations of 87 oncologists and patients interactions. 37 patients initially interviewed; 28 interviewed later; a further 11 interviews carried out with oncologists …

Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxaban.

Cancer-associated venous thromboembolism (VTE) is a frequent, potentially life-threatening event that complicates cancer management. Anticoagulants are the cornerstone of therapy for the treatment and prevention of cancer-associated thrombosis (CAT); factor Xa-inhibiting direct oral anticoagulants (DOACs; apixaban, edoxaban, and rivaroxaban), which have long been recommended for the treatment of VTE in patients without cancer, have been investigated in this setting. The first randomized comparisons of DOACs against low-molecular-weight heparin for the treatment of CAT indicated that DOACs are

Совпадение в полном тексте источника
… Views from oncologists, hematologists, surgeons, radiation oncologists, and members of the palliative care team responsible for treating CAT were collected. A questionnaire (available in 9 languages) was distributed, and the results are currently being analyzed. … Oncologist. 2014;19:82–93. 37. Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967–77. 38. …

Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities.

Subcutaneous delivery of biotherapeutics has become a valuable alternative to intravenous administration across many disease areas. Although the pharmacokinetic profiles of subcutaneous and intravenous formulations differ, subcutaneous administration has proven effective, safe, well-tolerated, generally preferred by patients and healthcare providers and to result in reduced drug delivery-related healthcare costs and resource use. The aim of this article is to discuss the differences between subcutaneous and intravenous dosing from both health-economic and scientific perspectives. The article c

Beyond dual targeting: redefining the treatment horizon for true extramedullary myeloma? - a critical appraisal.

The management of relapsed/refractory multiple myeloma with true extramedullary disease (EMD) remains a critical challenge. The phase 2 RedirecTT-1 study evaluated the combination of two bispecific antibodies, talquetamab (anti-GPRC5D) and teclistamab (anti-BCMA), in this high-risk population. While the reported overall response rate of 79% and 12-month progression-free survival of 61% are promising, a balanced interpretation requires caution. The single-arm design, short follow-up (12.6 months), and indirect comparisons with CAR-T therapy preclude definitive conclusions about comparative effe

Delivering bad news in clinical hematology: a personal perspective.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Assuming that their medical education makes them understand the common acronyms and technical details of hematology is not recommended, as with today’s specialization, we find that physicians who are not hematological oncologists are as bewildered about our field as are patients with no medical education …

Distress Screening among Patients with Hematological Malignancies: A Descriptive Cross-sectional Study.

IntroductionDistress is a major concern during diagnosis and treatment of hematological malignancies. The Distress Thermometer is a commonly used screening tool to detect distress. The objectives of this study was to know the prevalence and identify distress score among patients with hematological malignancies in Nepal.MethodsA descriptive cross sectional study was carried out at the Hematology Unit of Civil Service Hospital after obtaining an ethical approval from the Institutional Review Committee (reference number 931/076/077). A convenient sampling technique was used for this study. Statis

Совпадение в полном тексте источника
… Pirl WF Muriel A Hwang V Kornblith A Greer J Donelan K et al Screening for psychosocial distress: a national survey of oncologists J Support Oncol 2007 5 10 499 504 18240673 …

Bone metastases: Are we failing our patients?

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Encouragingly, the Skeletal Care Academy steering committee (composed of international experts in the field of cancer-related bone disease; oncologists, urologists, surgeons, nurses and patient advocacy groups) has put together a Patient Charter, setting out the basic requirements for standards of patient …

Prospective external validation of a three-predictor frailty model for 90-day survival and complications following spinal metastasis surgery.

Background contextSurgical decision-making in patients with spinal metastases remains complex due to the need to balance potential surgical benefits with limited survival and common frailty. Predictive models can assist in this process, but their clinical utility is often limited by complexity and lack of validation.PurposeTo externally validate a simple three-predictor frailty model for 90-day survival and complications, and to compare its performance with other commonly used tools.Study design/settingProspective external validation study conducted at a single tertiary cancer center.Patient s

Совпадение в полном тексте источника
… When using the Anzuategui model, we recommend thoughtful consideration when classifying tumor aggressiveness, avoiding overreliance on Table 7 and encouraging individualized assessment whenever possible, ideally involving multidisciplinary input from pathologists and medical oncologists. … Oncologist. 2013;18:744–751. doi: 10.1634/theoncologist.2012-0293. 45. Anzuatégui P.R., Mello G.J.P., Rigolino A.V.B. Lymphopenia predicts 30-day morbidity and mortality following spinal metastasis surgery. North Am. Spine Soc. J. 2021;6 doi: 10.1016/j.xnsj.2021.100062. 46. …

The role of AI in oncology: present applications and future horizons.

Artificial intelligence (AI) offers a powerful means to accelerate precision oncology by individualizing care in an era of rapidly evolving treatment paradigms. However, there is limited regulatory oversights for safe clinical implementation of AI, and concerns surrounding data bias, ownership, and privacy have hindered broad integration into healthcare practice. In this perspective, we offer a forward-looking roadmap for the dissemination of AI in oncology. We discuss the role for AI in guiding biomarker-driven patient selection for clinical trials and in facilitating both personalized drug s

Совпадение в полном тексте источника
… Yet, for many oncologists, terms like “AI” and “precision medicine” remain largely conceptual if not aspirational. While there is current authoritative guidance on the clinical trial implementation of AI, concerns surrounding data have hindered broad integration 1 – 3 . … This system has been used in innovative ways, such as automatically notifying oncologists via email when a solid tumor patient with panel DNA next-generation sequencing is matched to a trial. …

Disparities in clinical trial participation among older adult Medicare beneficiaries with hematologic malignancies from 2006 to 2019: A SEER-Medicare analysis.

BACKGROUND: Clinical trials (CTs) are essential for expanding treatment options across hematologic malignancies (HM) and providing access to novel treatments. However, older adults with HM are often underrepresented in CTs, and a national-level evaluation of factors influencing their participation is lacking. METHODS: The authors conducted a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, identifying patients ≥66 years old diagnosed with HM between 2006 and 2018 (follow-up to December 2019). CT participation was defined by Medicare cl

Совпадение в полном тексте источника
… Association between geographic access to cancer care, insurance, and receipt of chemotherapy: geographic distribution of oncologists and travel distance. J Clin Oncol. 2015;33(28):3177‐3185. doi: 10.1200/jco.2015.61.1558 48. Massarweh NN, Chiang YJ, Xing Y, et al. … Oncologist. 2019;24(6):e284‐e291. doi: 10.1634/theoncologist.2018-0803 70. Huang L‐W, Wang S. Cancer clinical trial enrollment in older vs younger adults. JAMA Netw Open. 2022;5(10):e2235718. doi: 10.1001/jamanetworkopen.2022.35718 71. …